Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last 60.05 INR
Change Today 0.00 / 0.00%
Volume 0.0
As of 7:05 AM 05/22/15 All times are local (Market data is delayed by at least 15 minutes).

bal pharma ltd (BLP) Snapshot

Open
60.60
Previous Close
60.45
Day High
61.40
Day Low
58.60
52 Week High
11/5/14 - 104.00
52 Week Low
06/3/14 - 27.65
Market Cap
773.0M
Average Volume 10 Days
12.8K
EPS TTM
0.39
Shares Outstanding
12.9M
EX-Date
09/12/14
P/E TM
154.3x
Dividend
1.00
Dividend Yield
1.67%
Current Stock Chart for BAL PHARMA LTD (BLP)

Related News

No related news articles were found.

bal pharma ltd (BLP) Related Businessweek News

No Related Businessweek News Found

bal pharma ltd (BLP) Details

Bal Pharma Limited manufactures and markets pharmaceutical formulations and active pharmaceutical ingredients (API) in India. The company offers prescription drugs, generics, OTC products, intravenous infusion products, and bulk actives. It also provides a range of APIs for therapeutic areas, such as acne treatment, diuretic, anti-histamine, anti-inflammatory, anti-diabetic, sedative/hypnotic, anti-allergy, neuropathic pain, urinary incontinence, anti-convulsant, and insomnia, as well as offers various finished formulations. The company also provides ayurvedic products comprising ANARSHA for regularize bowl movement; ASHWAMED for sexual and general debility; AYURFINE and AYURFINE FORTE, an anti arthritics for osteoarthritis, rheumatoid arthritis, and spondylitis; AYURSULIN for managing diabetes; IMMUWIN, an immune building supplement; and LIPIVED for reducing cholesterol. Its ayurvedic products also consist of MENOLEAP capsules and syrup for menstrual disorders; PROLIFE, which provides life to ailing liver; BALPRO SYRUP for stable and synchronized liver functions; PROSTOWIN for benign prostatic hyperplasia; STONEX for expulsion of kidney stones; SUJIRNA for digestion; SUSWAS, an antallergic/antiasthamatic product; and BALVAC, a mild laxative. The company also exports its products to Europe, Latin America, Africa, the Middle East, and Asian markets. Bal Pharma Limited was incorporated in 1987 and is based in Bengaluru, India.

Founded in 1987

bal pharma ltd (BLP) Top Compensated Officers

Managing Director, Executive Director, Member...
Total Annual Compensation: 6.0M
Whole-Time Director, Chairman of Banking Tran...
Total Annual Compensation: 2.7M
Compensation as of Fiscal Year 2014.

bal pharma ltd (BLP) Key Developments

Bal Pharma Limited Appoints Sarika Bhandari as Additional Director

Bal Pharma Ltd. has informed that the Board of Directors of the company at its meeting held on March 27, 2015 has appointed Ms. Sarika Bhandari as additional director on the Board of the company.

Bal Pharma Limited, Board Meeting, Mar 27, 2015

Bal Pharma Limited, Board Meeting, Mar 27, 2015. Agenda: To approve appointment of Ms. Sarika Bhandari as additional Director on the Board of the company.

Bal Pharma Limited Reports Unaudited Earnings Results for the Third Quarter and Nine Months Ended December 31, 2014

Bal Pharma Limited reported unaudited earnings results for the third quarter and nine months ended December 31, 2014. For the quarter, the company reported net sales/income from operations was INR 422.225 million against INR 432.762 million a year ago. Profit from operations before other income, finance costs and exceptional items was INR 26.139 million against INR 34.364 million a year ago. Profit from ordinary activities before tax was INR 10.418 million compared to INR 17.089 million for the same period a year ago. Net profit was INR 7.842 million or INR 0.81 basic and diluted earnings per share against INR 13.904 million or INR 1.32 basic and diluted earnings per share a year ago. For the nine months, the company reported net sales/income from operations was INR 1,325.18 million against INR 1,267.933 million a year ago. Profit from operations before other income, finance costs and exceptional items was INR 91.313 million against INR 97.466 million a year ago. Profit from ordinary activities before tax was INR 45.609 million compared to INR 46.818 million for the same period a year ago. Net profit was INR 34.661 million or INR 2.71 basic and diluted earnings per share against INR 37.144 million or INR 3.51 basic and diluted earnings per share a year ago.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
BLP:IN 60.05 INR -0.40

BLP Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for BLP.
View Industry Companies
 

Industry Analysis

BLP

Industry Average

Valuation BLP Industry Range
Price/Earnings 15.6x
Price/Sales 0.3x
Price/Book 1.4x
Price/Cash Flow 8.3x
TEV/Sales 0.1x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact BAL PHARMA LTD, please visit www.balpharma.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.